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Abstract
Our objective was to study the frequency of circulating CD19+CD24hiCD38hi B cells (Breg)
in AS patients. To this end, peripheral blood was drawn from AS patients naïve for TNF
blockers (AS/nb) (n = 42) and healthy controls (HC) (n = 42). Six patients donated blood for
a second time, 6 months after initiating treatment with anti-TNFα drugs. After isolation by
Ficoll-Hypaque, PBMCs were stained with antibodies to CD3, CD4, CD19, CD24, and
CD38, and examined by cytometry. For functional studies, total CD19+ B cells were isolated
from PBMCs of 3 HC by magnetical sorting. Breg-depleted CD19+ B cells were obtained
after CD19+CD24hiCD38hi B cells were removed from total CD19+ cells by cytometry. Total
CD19+ B cells or Breg-depleted CD19+ B cells were established in culture and stimulated
through their BCR. Secretion of IFNγ was determined by ELISA in culture supernatants.
When compared with HC, AS/nb patients demonstrated a significantly increased frequency
of Breg cells, which was independent of disease activity. Anti-TNFα drugs induced a signifi-
cant reduction of circulating Breg numbers, which were no longer elevated after six months
of treatment. Functional in vitro studies showed that the secretion of IFNγ was significantly
higher in Breg-depleted as compared with total CD19+ B cells, indicating that Breg can
downmodulate B cell pro-inflammatory cytokine secretion. In summary, an increased fre-
quency of circulating CD19+CD24hiCD38hi B cells is observed in AS/nb patients, that is not
related with disease activity; anti-TNFα drugs are able to downmodulate circulating Breg
numbers in AS.
Introduction
The pathogenesis of Ankylosing spondylitis (AS), the prototype form of Spondyloarthritis
(SpA), is not well understood, and evidence indicating a role for either autoinflammatory or
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autoimmune mechanisms has been described [1]. An interesting report by Cantaert et al [2]
has shown an increased number of IL-10 producing CD19+CD5+ B lymphocytes in SpA.
B cells are not merely a source of antibodies [3]; they also act as very efficient antigen pre-
senting cells and as cytokine producers [3]. In addition regulatory B cells, a subspecialized B
cell subset, contribute to the maintenance of peripheral tolerance by downmodulating T and B
cell function [4,5]. Phenotypical characterization of Bregs in mice or humans is not straightfor-
ward, and different definitions of Bregs have been proposed based on distinct cell surface
markers [6]; however, Bregs have not been demonstrated to constitute a unique cell lineage
[6]. Therefore, IL-10 production together with functional inhibition of T or B cell responses
remain the gold standard for Breg definition [6].
In human peripheral blood, immature CD19+CD24hiCD38hi B cells contain a high propor-
tion of IL-10 producing cells [7,8] and functionally behave as suppressors of Th1 responses
and Th17 differentiation [9]. In addition, CD19+CD24hiCD38hi B cells are able to induce Treg
and Tr1 phenotype from CD4+ T cells [9].
Patients with autoimmune conditions such as systemic lupus erythematosus (SLE) [7], RA
[9], primary Sjo¨gren0s syndrome [10], ANCA-associated vasculitis [11], and Systemic Sclerosis
[12,13], have been shown to demonstrate altered numbers and/or function of circulating
CD19+CD24hiCD38hi B cells. In addition, whereas Cantaert et al described an increased num-
ber of circulating CD19+CD5+ B cells with a regulatory phenotype in SpA [2], Chen et al
reported normal numbers of CD19+CD24+CD38+ B cells with decreased IL-10 production in
AS patients [14]. To our knowledge, these are the two only published reports on the numbers
of circulating B cells with regulatory properties in SpA. Therefore, our objective was to investi-
gate on the frequency of circulating CD19+CD24hiCD38hi B cells in AS and test the regulatory
capacity of this B cell subset.
Patients and methods
Ethics statement
The study was approved by the Hospital La Paz—IdiPAZ Ethics Committee (protocol number
HULP PI-883), and all subjects provided written informed consent according to the Declara-
tion of Helsinki.
Patients
Peripheral blood was obtained from 42 AS patients who had never received TNF blockers
(AS/nb) (Table 1 and S1 Table) and from 42 age and gender-matched healthy controls (HC)
(S2 Table). All subjects were studied between the years 2014 and 2016. Patients were recruited
among those attending the outpatient Rheumatology Clinic at Hospital Universitario La Paz
(Madrid, Spain). Inclusion criteria for patients were age greater than 18 years and AS diagnosis
according to the 1984 modified New York criteria [15], exclusion criteria were a history of pre-
vious treatment with biological agents and infection with HBV, HCV or HIV. Healthy controls
were recruited among hospital and laboratory workers. Inclusion criteria for controls were
age greater than 18 years; exclusion criteria for controls were current or chronic medication
intake, the presence of any known disease condition or infection with HBV, HCV or HIV.
Forty-seven patients were approached and 42 accepted to participate; fifty controls were
approached and 42 accepted to participate. There were no dropouts. Among patients, 28 were
taking non-steroidal anti-inflammatory drugs (NSAIDs), 7 were receiving sulfasalazine (SSZ);
3 methotrexate (MTX) and 7 of them did not take any medication regularly. 31 patients had a
pure axial disease (13 female, 18 male) and 11 patients (4 female, 7 male) had a combination of
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axial and peripheral manifestations (Table 1 and S1 Table). All subjects were of Western Euro-
pean descent.
Six AS/nb patients intitiated treatment with anti-TNFα antibodies (2 infliximab, 2 golimu-
mab, 1 adalimumab, 1 certolizumab). Four of them were male, and 5 were HLA B27+; age was
41.0 (33.0–59.5) years (median, IQR), duration of symptoms was 9.0 (2.0–19.5) years, time
since diagnosis 6.0 (0.5–12.0) years, and ASDAS-CRP 3.87 (2.38–4.48). These patients donated
blood on two occasions: right before the first dose of biological agent was administered, and 6
months thereafter. For each patient, one healthy subject served as control on both the first and
second occasion.
Isolation of B cells from human peripheral blood
Peripheral blood mononuclear cells (PBMCs) were separated immediately after blood sample
collection, by Ficoll-Hypaque (GE Healthcare Biosciences AB, Uppsala, Sweden) density
gradient centrifugation. Highly purified B cells were prepared from PBMCs by exhaustive
immunomagnetic negative selection in an Automacs (Miltenyi Biotec, Bergisch Gladbach,
Germany) using a B cell negative isolation kit (Miltenyi Biotec), containing biotinylated anti-
bodies against CD2, CD14, CD16, CD36, CD43, and CD235a (glycophorin A). The purity of
the isolated B cells as assessed by flow cytometry using a fluorochrome-conjugated anti-CD19
mAb was greater than 98%. Subsequently, Breg-depleted CD19+ B cells were obtained after
removing CD19+CD24hiCD38hi B cells from total CD19+ B cells by cytometry in a FacsVan-
tage SE sorter (Beckton Dickinson). The purity of Breg-depleted B cells was >98%.
B cell cultures
To assess the regulatory capacity of circulating CD19+CD24hiCD38hi B cells (Breg) on B cell
cytokine secretion, total CD19+ B cells or Breg-depleted CD19+ B cells (1x105 cells/well) were
cultured for 7 days in U-bottom 96-well plates containing RPMI 1640 medium (Lonza, Alen-
dale, NJ, USA) with 10% FCS, 2 mM L-glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin
and 50 mM 2-mercaptoethanol, in the presence of 10μg/ml F(ab’)2 Goat Anti-Human
IgM+IgG Functional Grade Purified (eBioscience). Secretion of IFNγ was determined by
ELISA in culture supernatants at different time points.
Table 1. Clinical characteristics of AS/nb patients.
AS/nb (n = 42)
Age (years); median (IQR) 52 (39.5–62)
Male; n˚ (%) 25 (59.5)
HLA-B27+; n˚ (%) 35 (85.4)
Duration of symptoms (yrs); median (IQR) 20.5 (10.0–34.5)
Time since diagnosis (yrs); median (IQR) 10 (4–19)
BASDAI; median (IQR) 4.6 (3.05–6.80)
BASFI; median (IQR) 2.9 (0.85–5.70)
ASDAS-ESR; median (IQR) 2.27 (1.92–3.38)
ASDAS-CRP; median (IQR) 2.80 (2.04–3.70)
CRP; median (IQR) 7.92 (3.25–12.45)
ESR; median (IQR) 9 (5.5–14.0)
AS/nb: AS patients naïve for TNF blockers
https://doi.org/10.1371/journal.pone.0180726.t001
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Cell surface staining and flow cytometry
The frequency and phenotype of Breg cells present in the peripheral blood of AS patients and
HC was assessed by flow cytometry after staining freshly isolated PBMCs with antibodies
directed to surface phenotypical markers. Fluorochrome-conjugated mAbs from BD Pharmin-
gen (San Diego, CA, USA) were used to examine the expression of CD3, CD4, CD19, CD24
and CD38 in a FACSCalibur flow cytometer with CellQuest software (BD Biosciences).
ELISAs
Cell-free culture supernatants were collected and stored at -80˚C. The concentration of IFNγ
was determined by ELISA using a kit from BD Biosciences and following the manufacturer0s
instructions. Serum calprotectin was determined by ELISA with a kit from Hycult Biotech
(Ulden, The Netherlands).
Statistical analysis
Comparison between groups was by Mann-Whitney test. Paired samples were compared
using a Wilcoxon matched pairs signed rank sum test. Correlations were analyzed using Spear-
man’s rank correlation coefficients. P values less than 0.05 were considered significant. All
analyses were performed using Prism version 5.0 software (GraphPad Software).
Results
Patients with AS/nb demonstrate increased numbers of circulating CD19
+CD24hiCD38hi B cells
We first sought to examine the expression of Breg phenotypical surface markers on CD19+ B
cells present in the peripheral blood of AS/nb patients. The absolute numbers of circulating
total CD19+ B cells were not different in AS/nb as compared with healthy control subjects:
median (IQR), 151.7 (105.8–216.7) in AS/nb vs 131.6 (90.71–165.8) x103/ml in HC, p>0.1. In
contrast, both the frequency and the absolute number of circulating CD19+CD24hiCD38hi B
cells, were significantly increased in AS/nb patients naïve for TNF blockers, as compared with
HC: median (IQR) 4.46% (3.08–6.20%) or 6.69 x103/ml (3.98–11.24 x103/ml) in AS/nb vs
3.28% (2.36–4.27%) or 4.17 x103/ml (3.11–5.58 x103/ml) in HC, p<0.01 (Fig 1).
Relation of circulating CD19+CD24hiCD38hi B cell frequency with
disease activity
The frequency of CD19+CD24hiCD38hi B cells did not correlate significantly with BASDAI,
CRP, ESR, ASDAS-CRP or ASDAS-ESR (Fig 2A). Patients with AS/nb demonstrated signifi-
cantly elevated levels of serum calprotectin as compared with controls (p<0.001) (Fig 2B).
Serum calprotectin correlated significantly with CRP and ASDAS-CRP but not with the fre-
quency of circulating CD19+CD24hiCD38hi B cells (Fig 2C).
Treatment with anti-TNF agents is associated with a significant reduction
of circulating CD19+CD24hiCD38hi B cell numbers in AS patients
We then sought to determine whether treatment with anti-TNFα agents is able to modify the
altered numbers of Breg cells observed in the peripheral blood of AS/nb patients. Six AS
patients previously naïve for TNF blockers and who had an incomplete response to NSAIDs,
donated blood right before the initiation of an anti-TNFα monoclonal antibody, and six
months thereafter. Blood was also obtained from six healthy subjects, who acted as controls for
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each patient at both the first and 6-month examination. When compared with basal data, at
the six month evaluation all 6 AS patients demonstrated a marked reduction in the frequency
of circulating Breg cells (p<0.05), whereas experimental variation observed in healthy controls
was minimal (p>0.1) (Fig 3A). At the same time, decreased values of CRP (p<0.05), calprotec-
tin (p<0.05) and ASDAS-CRP (p<0.05) were observed in all patients (Fig 3B). Four of these
patients experienced a major clinical improvement as determined by a reduction of the
ASDAS-CRP index greater than 2.0 units [16].
Negative regulatory capacity of CD19+CD24hiCD38hi B cells
Total CD19+ or Breg-depleted CD19+ B cells (B cells depleted of CD19+CD24hiCD38hi cells)
were isolated from the peripheral blood of three healthy controls (HC), established in culture
and stimulated with anti-IgM+IgG MoAbs. Secretion of IFNγ was determined in culture
supernatants by sandwich ELISA at 2, 5 or 7 days. When compared with total CD19+ B cells,
Breg-depleted CD19+ B cells secreted an increased amount of IFNγ at all tested time points (2,
5 and 7 days) (Fig 4).
Discussion
We have herein described an increased frequency and absolute number of CD19+CD24hi
CD38hi B cells in AS patients naïve for biological agents, that is not related with disease
Fig 1. Numbers of circulating CD19+CD24hiCD38hi B cells in AS patients naïve for TNF blockers (AS/
nb). PBMCs isolated from the peripheral blood of AS/nb patients (n = 42) and from age and gender-matched
healthy controls (HC) (n = 42) were stained with fluorochrome-labeled antibodies against cell surface markers
and examined by flow cytometry. AS/nb patients showed an increased proportion and absolute numbers of
circulating CD19+CD24hiCD38hi B cells. A. Representative dot plots demonstrate CD24 and CD38
expression in cells gated for CD19. B, C. Frequency (B) and absolute numbers (C) of circulating CD19
+CD24hiCD38hi B cells in HC and AS/nb patients. Bars represent the median and interquartile range.
*p<0.01.
https://doi.org/10.1371/journal.pone.0180726.g001
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activity measures. These results parallel data published by Cantaert el al, who reported on
elevated numbers of CD19+CD5+ B cells with a regulatory phenotype in SpA, independent
of disease activity [2]. Assessment of clinical activity in SpA is difficult due to the lack of a
universally accepted ‘gold standard’ [16], and because some of the currently used indices
measure only one aspect of the disease or are mostly patient or physician oriented. Therefore
we were interested in ascertaining whether the lack of correlation of Breg cell numbers with
ASDAS-CRP was relevant. Serum calprotectin has recently emerged as a good biomarker for
disease activity in SpA [17,18] and we observed that serum calprotectin concentrations were
significantly correlated with CRP and ASDAS-CRP but not with the percentage of circulat-
ing Breg cells, thereby confirming that Breg cell numbers do not vary with disease activity in
AS.
The gold standard for Breg cell definition remains the ascertainment of their regulatory
capacity [6]. We observed that Breg-depleted CD19+ B cells secreted increased amounts of
IFNγ as compared with total CD19+ B cells, indicating that Breg downregulate pro-inflamma-
tory B cell cytokine secretion. Breg cells have been described to negatively modulate T cell
responses [4–7] and downmodulate CD86 expression on B cells [8]. Our results indicate an
Fig 2. The frequency of circulating CD19+CD24hiCD38hi B cells in AS/nb patients is not related
with disease activity scores and/or inflammatory serological markers. A. The frequency of
CD19+CD24hiCD38hi B cells is not related with BASDAI, CRP, ESR, ASDAS-CRP or ASDAS-ESR. B. AS/
nb patients demonstrate increased levels of calprotectin as compared with HC. *p <0.001 C. Serum
calprotectin concentrations were significantly correlated with CRP and ASDAS-CRP but not with the
frequency of CD19+CD24hiCD38hi B cells.
https://doi.org/10.1371/journal.pone.0180726.g002
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autoregulatory action of Breg cells on B effector cell cytokine secretion, and this is an aspect of
Breg function which had not been described previously.
The contribution of adaptive immunity to the pathogenesis of AS has not been established
[1] and the possible role of increased Breg cells in the peripheral blood of AS patients does not
Fig 3. Treatment with anti-TNF agents is associated with a significant reduction of circulating CD19
+CD24hiCD38hi B cell numbers in AS patients. A. Frequency of CD19+CD24hiCD38hi B cells in six AS
patients before and six months after initiating treatment with anti-TNFα agents, and in their 6 age and gender-
matched healthy controls at the basal and 6 month study. (*p<0.05) B. CRP, calprotectin and ASDAS-CRP
values in these 6 AS/nb patients before and six months after initiating treatment with anti-TNFα. (*p<0.05)
https://doi.org/10.1371/journal.pone.0180726.g003
Fig 4. Suppressive capacity of CD19+CD24hiCD38hi B cells in healthy subjects. Total CD19+ or B cells
depleted of CD19+CD24hiCD38hi cells (Breg-depleted CD19+ B cells), isolated from the peripheral blood of
three healthy controls (HC), were established in culture, and stimulated with anti-IgM+IgG. Secretion of IFNγ
was determined in culture supernatants by sandwich ELISA at 2, 5 or 7 days. Bar graphs represent the mean
and SEM for IFNγ concentrations of 3 independent experiments.
https://doi.org/10.1371/journal.pone.0180726.g004
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have a straightforward explanation. One likely possibilty is that augmented Breg numbers are
a reflection of chronic immune system stimulation at the gut. In fact, AS patients demonstrate
an altered gut microbiome [19], which may be influenced by HLA-27 [20]. In addition, an
increased intestinal permeability has been described not only in patients with AS but also in
their healthy relatives [21]. Furthermore, subclinical gut inflammation can be observed in up
to 65–70% of AS patients [22]. It is associated with an increased amount of local lymphoid fol-
licles [23] and with a pro-angiogenic intestinal phenotype [24], that can facilitate an enhanced
trafficking of immune cells.
Of note, the gut microbiota has been shown to be involved in the development of several
autoimmune / autoinflammatory conditions including arthritis [25–27]. At the same time, it
plays an important role in the generation of Breg cells thereby providing a negative feedback
for inflammation [26,27]. Interestingly, the gut microflora is able to induce Breg differentia-
tion not only at the intestinal lymphoid tissue, but also at the spleen [27]; this may indicate the
existence of B cell trafficking from the gut to other organs [27], and/or the effect of specific gut
microbiota metabolites signaling at distant sites [28].
In this context, there is evidence for an increased frequency of circulating CD19+/ CD38hi/
CD24hi/IL-10+ B cells in active IBD patients as compared with inactive disease or healthy con-
trols [29], suggesting that Breg cells may act downregulating gut inflammation in patients with
disease activity [29].
Importantly, whereas Breg numbers were significantly increased in our AS patients naïve
for biological agents, independently of disease activity parameters, we observed that treatment
with anti-TNFα was associated with a reduction of circulating Breg cell numbers. We can spec-
ulate that this is reflecting a modification of microbiome composition, gut barrier integritiy,
and/or an improvement of subclinical gut mucosal inflammation that is only achieved by this
treatment, given the leading role of TNFα in gut homeostasis and in the pathogenesis of
inflammatory bowel disease [30–34]. Also, a potent downregulation of inflammatory media-
tors by anti-TNFα treatment may lead to reduced Breg numbers, given the dependency of
Breg cell generation on the local inflammatory milieu [6].
This study is limited by the high amount of blood required for functional assays, which
hampered the recruitement of patients for this purpose, and by the absence of clinical /labora-
tory data on subclinical gut inflammation or microbiota composition of our patients.
Conclusion
In summary, we have described increased numbers of circulating CD19+CD24hiCD38hi B
cells (Breg) in AS/nb patients, that are not related with disease activity. Treatment with anti-
TNFα drugs is able to downmodulate circulating Breg cell numbers in AS.
Supporting information
S1 Table. Clinical data of AS/nb patients.
(DOCX)
S2 Table. Age and gender of healthy controls.
(DOCX)
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